Abstract
Purpose: The optimal integration of chemotherapy with radiation (RT) for patients with early-stage breast cancer remains uncertain. We present the long-term results of a prospective randomized trial to address this question. Patients and Methods: Two hundred forty-four patients were randomly assigned after conservative breast surgery to receive 12 weeks of cyclophosphamide, doxorubicin, methotrexate, fluorouracil, and prednisone (CAMFP) before RT (CT-first) or after RT (RT-first). Median follow-up for surviving patients was 135 months. Results: There were no significant differences between the CT-first and RT-first arms in time to any event, distant metastasis, or death. Sites of first failure were also not significantly different. Conclusion: Among breast cancer patients treated with conservative surgery, there is no advantage to giving RT before adjuvant chemotherapy. However, this study does not have enough statistical power to rule out a clinically important survival benefit for either sequence. © 2005 by American Society of Clinical Oncology.
Cite
CITATION STYLE
Bellon, J. R., Come, S. E., Gelman, R. S., Henderson, I. C., Shulman, L. N., Silver, B. J., … Recht, A. (2005). Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial. Journal of Clinical Oncology, 23(9), 1934–1940. https://doi.org/10.1200/JCO.2005.04.032
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.